INO-4800 DNA Coronavirus Vaccine Uses, Dosage, Side Effects and more
INO-4800 DNA Coronavirus Vaccine is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19. Early in vitro studies using HEK-293T cells demonstrated that the transfection of INO-4800 DNA Coronavirus Vaccine results in the expression of S protein by human cells. Follow up studies in both BALB/c mice and Hartley guinea pigs demonstrated the ability of INO-4800 DNA Coronavirus Vaccine to induce both humoral and T cell-mediated immunity against SARS-CoV-2, including in the lungs. Furthermore, the antibodies produced were capable of inhibiting the binding of SARS-CoV-2 to the ACE2 receptor, which is thought to be critical for host cell entry.
A Phase 1 clinical trial for INO-4800 DNA Coronavirus Vaccine in the U.S. (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021. A Phase 1/2 clinical trial through South Korea's Seoul National University Hospital was announced on June 4, 2020, and expected to start later in the month.
| Attribute | Details |
|---|---|
| Trade Name | INO-4800 DNA Coronavirus Vaccine |
| Generic | INO-4800 |
| INO-4800 Other Names | INO-4800 DNA Coronavirus Vaccine |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
